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Background. The NORSTENT trial randomized 9013 patients to percutaneous coronary 
intervention (PCI) with drug-eluting or bare metal stents with five years follow-up. No 
difference was found in the composite primary outcome of death from any cause and nonfatal 
spontaneous myocardial infarction after a median of 5 years of follow-up.  Secondary 
outcomes included repeat revascularizations, which were reduced by drug-eluting stents.  The 
present study reports the occurrence of target lesion revascularization (TLR) in time and 
across demographic and clinical subgroups in patients with lesions in native coronary arteries 
(n = 8782). 
Results. Clinically driven TLR was performed in 488 (5.6%) of the 8782 patients during 5 
years of follow-up. Male gender, older age, visible thrombus in the lesion and larger  stent 
diameters were associated with less TLR, whereas multivessel disease and longer stents were 
associated with higher risk of TLR. There was a substantial and highly significant reduction in 
the hazard for any TLR after 5 years in the drug-eluting stent group (HR 0.44, [95% CI 0.36 – 
0.52], p < .001).  The effect of drug-eluting stents on TLR was limited in time to the first 2 
years in the study without evidence of a later rebound effect. The reduction in TLR by drug-
eluting stents was consistent across subgroups defined by gender, age, diabetes status, renal 
function, and lesion and stent characteristics. The number needed to treat with drug-eluting 
stents compared to bare metal stents to prevent one TLR ranged from 4 to 110 across 
clinically relevant subgroups. 
Conclusion. Drug-eluting stents have a time limited effect on the rate of TLR, but with a 
substantial and highly significant reduction in the first 2 years after the procedure. This effect 
was found to be consistent across all important clinical subgroups. 
  
INTRODUCTION 
Percutaneous coronary interventions (PCI) with implantation of bare metal (BMS) or drug-
eluting stents (DES) are frequently performed with millions of patients treated each year 
worldwide [1, 2]. DES generally reduce the rate of restenosis after intervention compared to 
BMS [1, 3]. The Norwegian Coronary Stent Trial (NORSTENT)  randomized 9013 patients to 
DES or BMS (ClinicalTrials.gov number, NCT00811772) and reported no significant 
difference between DES and BMS for the main composite endpoint of death of any cause and 
non-fatal spontaneous myocardial infarction [4]. The rates of revascularization were 
significantly lower after the use of DES compared to BMS with a hazard ratio (HR) for target 
lesion revascularization (TLR) of 0.47 (95 % confidence interval [95% CI] 0.40 – 0.56). 
Several studies have reported predictors for TLR with variable results. Younger age, diabetes 
and lesion complexity including stent length and multiple lesions have been suggested in  
some studies to be risk factors for TLR [5-9], but not all [10]. We have not identified larger 
randomized studies reporting predictors for TLR with second generation DES compared to 
thin strutted BMS, and no studies evaluating separate predictors for DES and BMS. 
The aim of the present study was to evaluate the effects of DES versus BMS on TLR for 
heterogeneity across demographic and clinical subgroups, lesion characteristics and follow-up 
time in native coronary arteries. Further, we aimed to estimate multivariable models to predict 
TLR in important clinical subgroups and to investigate potential risk factors for TLR 
separately and together for DES and BMS. 
  
METHODS  
NORSTENT was a multicenter, randomized trial conducted at all centers in Norway 
performing PCI. The main study including the study protocol has previously been reported 
[4]. The trial was funded by the Norwegian Research Council and other non-profit 
organizations and approved by the Norwegian Regional Committee for Medical and Health 
Research Ethics – Region North. The patients were included in the study from September 15, 
2008 to February 14, 2011. NORSTENT was an “all-comer” trial with broad inclusion criteria 
and few exclusion criteria [4]. Double platelet inhibition with aspirin and clopidogrel was 
prescribed for 9 months regardless of randomized assignment. Clinical follow-up was 
performed according to the routine practice at each center without any routine follow-up with 
coronary angiography. The manual for definitions and classifications of outcomes was 
provided in the Supplementary Appendix to the main study. Definite stent thrombosis was 
defined according to the Academic Research Consortium Criteria [11]. Non-fatal outcomes 
were collected by linkage to the Norwegian Patient Registry through December 31, 2014, 
with use of the unique 11-digit Norwegian national identification number for each patient. 
The date and cause of death were obtained by linkage to the Norwegian Causes of Death 
Registry. All outcomes were adjudicated by an end-point committee consisting of clinical and 
interventional cardiologists and an epidemiologist blinded for the patients’ treatment 
assignment.   
The endpoint TLR was defined as clinically driven PCI of the target lesion for restenosis or 
other complication of the index lesion or coronary artery bypass surgery (CABG) to the target 
vessel. The patient level outcomes were evaluated in the whole cohort excluding patients with 
treated vein grafts or arterial grafts (n = 229). The lesion level outcomes were assessed in the 
subgroup with only one lesion treated in a native coronary artery to ensure that the actual 
characteristics of that lesion were those related to TLR.  When more than one lesion was 
treated in the index procedure the TLR data did not allow the identification of which lesion 
had to be retreated. 
 
Statistical analyses 
Differences among categorical variables at baseline were tested with Fishers exact test or chi-
square test in case of excessive permutations. The purpose of the remaining analyses was to 
compare the rates and risk factors for TLR across subgroups in patients randomized to 
treatment with BMS or DES. 
Subgroup analyses 
Cumulative failure rates at specific time points were estimated with the Kaplan-Meier method 
and cumulative incidence functions. Subgroup-specific hazards were identified using Cox 
regressions which were all stratified for study center. The presence of important heterogeneity 
of the treatment effect of DES versus BMS on TLR across subgroups was assessed by 
including treatment-subgroup interactions as cross product terms in the model, requiring 
p<0.01 for claiming significance due to many comparisons. Cox regression and Royston-
Parmar models were used to identify time-dependent effects [12].   The best fitting Cox model 
was identified based on maximum log-likelihood.   The assumption of proportional hazards 
was tested using Schoenfeld residuals and continuous variables were tested for linearity on the 
hazard scale by quartile plots.  
 
Multivariable TLR prediction model. 
The Royston-Parmar model was used to compare multivariable survival between DES and 
BMS overall and in each stent group. A basic prediction model was built from the 
demographic and clinical covariates by backwards elimination, and thereafter adding 
variables describing properties of the stents and lesions, model selection being guided by 
likelihood-ratio tests.  Martingale residuals were used to assess goodness-of-fit. The final 
model was tested for time varying covariates and for interaction between covariates, as well 
as   recasted as a competing risk model to assess any impact of all-cause mortality on the 
estimated hazards for TLR. The number needed to treat for benefit (NNT) was calculated as 
the reciprocal value of the survival difference. All analyses were performed in STATA v.14 
(Collage Station, Tx, USA) and the STATA programs stpm2 and stpm2cr were used for 




In the complete cohort of 9013 patients, 226 had their index lesion in vein grafts, three in 
arterial graft and one patient had missing information, leaving 8782 patients in the study. In 
this cohort target lesion revascularization was performed in a total of 575 patients (6.5%) of 
which 488 patients (5.6%) were treated with PCI and 87 treated with CABG. The sum of TLR 
from both treatments in the cohort with lesions in native coronary arteries was used as the 
endpoint in the analyses. Lesion and stent characteristics in relation to TLR were analyzed in 
the subgroup of patients with only one lesion treated (n= 6087) in native arteries. In that 
cohort there were 277 (4.6%) patients treated with PCI and 56 (0.9%) treated with CABG. In 
the DES group 83.5% of the stents implanted at baseline were everolimus-, 11.6% 
zotarolimus-, 2.5% sirolimus- and 2.4% paclitaxel-eluting stents.  Thus, the number of first-
generation drug-eluting stents were too few to warrant separate analyses. 
During a median of 59 months of follow-up TLR occurred in 3.5 % vs 7.6 % of patients in the 
DES and the BMS group, respectively (p < .001), see Table 1. The distribution of the clinical 
indications for TLR treated with PCI only, differed in the DES and the BMS groups. 
Myocardial infarction occurred relatively more frequently, and stable angina occurred less 
frequently in the DES group than in the BMS group (p = .001, Table 1).  No difference in the 
use of platelet inhibition between the DES and BMS groups could be detected from a 
questionnaire 6 months after the index procedure (p= 0.84). 
Multivariable Cox regression with all significant baseline variables on patient level revealed 
that TLR was neither related to all-cause mortality (HR 0.90, [95% CI 0.63 – 1.28], p = .56), 
nor to cardiac mortality (HR 0.72, [CI 0.35 – 1.46], p = .36) in the population with lesions in 
the native arteries (n = 8782).   
In the total population with TLR in native coronary arteries there was a substantial and highly 
significant reduction in the rate of any TLR in the DES group after 5 years (HR 0.44, [0.36 – 
0.52], p < .001). In the subgroup with only one treated lesion the HR for DES was 0.40 (0.31 
– 0.50, p < .001). Kaplan-Meier failure estimate was used to calculate the rate of TLR events 
in baseline subgroups at specific time points. The influence of total mortality as competing 
event was assessed with the same Kaplan-Meier estimate in the subgroup without mortality, 
yielding virtually identical results. In addition, competing risk regression with total mortality 
as competing event yielded comparable results to the Kaplan-Meier estimate. The cumulative 
rates of TLR for DES and BMS in different baseline subgroups after 5 years are depicted in 
Table 2 on patient level and in Table 3 on lesion level. The influence of each baseline variable 
on TLR rates together with the p-value of the interaction term between stent type and 
covariate on patient level and lesion level is given in Table 1 and Table 2 in Supplementary 
appendix.  The rate of TLR seems to decrease with increasing age and more so in the BMS 
group. However, the interaction term between age and randomized stent was not significant (p 
= 0.90). The impact of diabetes on TLR rate was modest and elevated values of serum 
creatinine had no effect. Number of diseased vessels increased the absolute TLR rate without 
significantly affecting the HR for randomized stent.  The TLR rate increased with longer stent 
lengths and decreased with increasing stent diameter and the presence of visible thrombus in 
the index lesion without affecting the HR for the effect of DES versus BMS.   No interaction 
term was significant at the 0.01 level. 
Time varying effect of randomized stent type  
In Cox regression with type of stent as the only covariate the interaction with time was highly 
significant (p < .001) with time split at 500 days as the best fitting model. Landmark analysis 
revealed HR for DES of 0.29 (0.23 – 0.36, p < .001) in the first 500 days and 1.07 (0.79 – 
1.45, p = .66) after 500 days with proportional hazard within each time period. A Royston-
Parmar model on the hazard scale with randomized stent as the only covariate, allowed to 
vary over time revealed similar results, and is illustrated in Figure 1. The HR is initially very 
low (HR 0.25) indicating a substantial initial effect of DES on the risk of TLR rate, but the 
HR increases with the elapse of time and the effect of DES compared to BMS is no longer 
significantly different after about one to two years. 
 
 
Multivariable TLR prediction model 
The model was constructed in the patient cohort with only one treated lesion in native 
coronary arteries (n = 6087), as described under statistics. The final model contained 7 
significant baseline covariates.  In this model height could be viewed as a proxy for gender 
and substituting gender for height affected the model minimally as judged by the log 
likelihood. Randomized stent was the only covariate with a statistically significant interaction 
with time. None of the interactions between the covariates were more than of borderline 
significance and with minimal impact on the predictions.  For simplicity the model is 
therefore presented without interactions.  An identical model analyzed with all-cause 
mortality as competing risk gave virtually identical results (not shown). The HRs for the final 
model are given in Table 4.  A plot of baseline hazard for DES and BMS from this model 
indicated increased hazard for BMS up to about 2 years with identical hazards thereafter 
(Figure 1, Supplementary appendix).  Separate modelling of predictors for TLR in BMS and 
DES patients basically revealed similar predictors, but with less importance of stent diameter 
in DES and increased TLR in chronic occlusion in BMS but not in DES (Supplementary 
appendix table 3 and 4). The test for interaction between chronic occlusion and stent treatment 
was not significant in the full model (p=0.16).  When forced into either of these models 
diabetes and serum creatinine were not significant predictors.   
 
Number-needed-to-treat in clinical subgroups 
 From the model in table 4 a wide range of NNT after 5 years can be calculated from the 
covariate values.  Selecting realistic clinical values for the covariates the range of NNT is 
from about 4 to 110.  Figure 2 shows examples of differences in survival free of TLR in a 75-
year-old male and 50-year-old female in one- two- and three-vessel disease with short stents 
(15 mm) with a large diameter (3.5) and no visual thrombus in the lesion with NNT indicated 
in each case. 
  
DISCUSSION. 
DES have consistently been shown to reduce the rate of restenosis and target vessel 
revascularization in multiple studies [13-15, 1, 3]. However, randomized trials have had 
limited generalizability and statistical power due to sample size and selection of patients [16-
18].  Our study was large with 9013 randomized patients. That amounted to 43.6 % of all PCI 
procedures in Norway performed in the study period and included 72.5 % of all eligible 
patients. The most frequent criteria for ineligibility was previous stent treatment [4].  
In our study DES caused a consistent, significant and substantial reduction in TLR across all 
subgroups (Table 2 and 3) and with no evidence of heterogeneity across subgroups when 
tested for interaction in a Cox regression. In addition, TLR seemed to be a benign event 
causing no increase in all-cause or cardiac mortality during a follow-up period of 5 years even 
though a considerable percent of indications for TLR was myocardial infarction (Table 1). 
This is in contrast to previous observations [19, 9, 20]. The reason for this discrepancy is not 
immediately apparent. A type II error can never be completely ruled out, but it is of note that 
in the study of Palmerini et al. [20] the excess mortality of TLR  was only slightly increased 
(HR 1.23, [CI 1.04 – 1.45], p = .02) and Parasca et al. [9] found significant differences in the 
composite endpoint, but not in total mortality. Thus, our observation might not be so much at 
odds with previous reports in claiming that TLR is a relative benign event. 
Interestingly the indications for TLR differed in the two stent groups (Table 1). The clinical 
presentation in DES treated patients was more often myocardial infarction than in BMS. If 
collapsing the categories of unstable angina and myocardial infarction so that the indications 
just were stable and unstable situations no difference between the indications of stent types 
was observed. Thus, it seems that the process leading up to TLR more often ends up in an 
infarction in DES treated patients and this did not seem to be related to the use of platelet 
inhibition.  Differences in angioscopic appearance and tendency of thrombus development 
between BMS and DES  as well as pathological studies might explain that observation [21-
23]. 
Our analyses revealed that the effect of DES  on the reduction in the rate of TLR development  
lasted up to 1.5 – 2 years with no additional benefit after that time, and with no indication of 
“catch-up” in TLR by BMS later in the observation period. Thus, the duration of the clinical 
effect of DES concerning TLR in this study seems to be in concert with previous reports [6, 
24]. 
Concerning predictors for TLR the variables in table 4 have also been described as significant 
in other reports [25, 8], except for visible thrombus in the index lesion. We have only found 
one report with a limited study population where thrombus in the lesion was included as a 
baseline variable [25].  They reported a non-significant trend towards less restenosis in lesions 
with thrombi. The reason for this is not obvious but could possibly be related to the 
occurrence of thrombi also in otherwise moderate plaques.  Further studies are needed to 
corroborate this observation.  Separate modelling of predictors in the BMS and DES group 
revealed similar results except for chronic total occlusion which was a significant predictor in 
BMS but not in DES patients and lesser influence of stent diameter in DES patients. We have 
found no previous report describing this in a randomized study, but they seem to be in concert 
with previous observations [6, 26, 8].  
 In the full multivariable model, no significant interaction between randomized stent and the 
other variables was found, consequently the use of drug-eluting stent would be beneficial in 
all subgroups with a reduced hazard ratio for the development of TLR. The magnitude of the 
absolute difference in survival free of TLR would depend on the underlying baseline hazard 
rate in each subgroup and can be evaluated with calculations of NNT.  The  model indicates 
less benefit in the older and male population, and as expected with short stents with large 
diameters, in concert with previous observations [25, 8].  We calculated the range of  NNT in  
selected clinically relevant subgroups  from 4 to 110, a range comparable to Tu et al. [6]. 
Since the TLR procedure does not seem to carry any additional mortality risk in our study the 
reasons to not use DES would be mainly economic and patient inconvenience for a new 
intervention. To decide what number needed to treat should indicate that one could use BMS 
instead of DES is a matter of subjective judgement, but it might be justified to claim that with 
an NNT in the region of 50-60 the benefit of using DES is negligible. Thus, the clinical 
benefit from using DES in elderly men with large stents is definitely limited (figure 2).  
However, as stated we have found no subgroup where DES does not perform better than 
BMS. 
Our results are based on the largest randomized study of DES versus BMS reported, and it is 
not likely that a study of the same size will ever be conducted again. It is therefore of great 
interest that no evidence of heterogeneity in the effect of DES compared to BMS for TLR was 
found.  Subgroup analyses of the primary end-point were reported in the main article [4], and 
are basically repeated here for the development of TLR. All subgroup analyses must be 
viewed as hypothesis generating and not as solid evidence and the individual p-values must be 
viewed with caution. Nevertheless, the consistency of the DES effect on TLR is impressive 
and despite the high number of analyses performed, not in a single comparison was BMS 
better than DES. 
In conclusion our study showed a consistent effect of DES in preventing TLR across all 
subgroups. The effect was time limited vanishing after about 1.5 years, but with no evidence 
of rebound phenomenon after that time and up to 5 years of observation. The baseline hazard 
for the development of TLR varied considerably as reflected in the wide range of observed 
number needed to treat. In recent guidelines  [27]  new-generation DES is in general preferred 
to BMS. However, since TLR seems to be a benign event without excess mortality the clinical 
benefit of using DES in the low risk subgroups for TLR is limited. 
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Legend to figures. 
 
Legend to figure 1. 
The figure shows the Royston-Parmar model on the hazard scale with randomized stent as a 
time varying covariate. HR, hazard ratio; CI, confidence interval. 
 
Legend to figure 2.  
Survival free of TLR in subgroups with short stents (15 mm) with relatively large diameters 










Table 1.  Clinical indication for target lesion revascularization with PCI in patients with 





n (%)/N * 
DES 
n (%)/N  
 
BMS 
n (%)/N  
 
All TLRs 488 (5.6)/8782  156 (3.5)/4403  332 (7.6)/4379  
Stable angina 221 (45.3)/488   65 (41.7)/156 156 (47.0)/332 
Unstable angina 94 (19.3)/488 19 (12.2)/156 75 (22.6)/332 
MI (all) 165 (33.8)/488 70 (44.9)/156 95 (28.6)/332 
MI with stent 
thrombosis  
45 (9.2)/488 20 (12.8)/156 25 (7.5)/332 
MI without stent 
thrombosis 
120 (24.5)/488 50 (32.1)/156 70 (21.1)/332 
Unknown indication 8 (1.6)/488 2 (1.3)/156 6 (1.8)/332 
Abbreviations: DES, drug-eluting stent; BMS, bare-metal stent; MI, myocardial infarction 
* n = number of events during follow-up in indicated group and percent experiencing the 
event in brackets (%), N = sample size in indicated group.   P=0.001 (Fishers exact test) for 
distribution of indications between stent types. 
 
  
Table 2.  Target lesion revascularization in baseline variables at patient level after 5 years in 
native coronary arteries. 
     
  TLR 
rates * 
 DES vs. BMS ┼ 









Subgroup  n (%) n (%) n (%)  HR (95% CI) p 
Total population  560 (6.6) 174 (4.1) 386 (9.1)  0.44 (0.36 - 0.52) <0.001 
Age  








0.45 (0.34 – 0.59) 
 
<0.001 
      60-79 years  303 (6.5) 90 (3.9) 213 (9.1)  0.41 (0.32 – 0.52) <0.001 
      >79 years  23 (4.7) 10 (3.9) 13 (5.7)  0.68 (0.30 – 1.57) 0.37 
Gender        
     Male  406 (6.4) 123 (3.9) 283 (8.9)  0.42 (0.34 – 0.52) <0.001 
     Female  154 (7.3) 51 (4.9) 103 (9.7)  0.47 (0.34 – 0.66) <0.001 
Current smoker        
    Yes  183 (6.1) 57 (3.9) 126 (8.2)  0.45(0.33 – 0.62) <0.001 
    No  332 (7.0) 97 (4.1) 235 (10.0)  0.39 (0.31 – 0.50) <0.001 
BMI         
    <25 kg/m2  163 (6.3) 49 (3.9) 114 (8.6)  0.43 (0.31 – 0.61) <0.001 
    25-35 kg/m2  358 (6.8) 110 (4.2) 248 (9.5)  0.42 (0.33 – 0.52) <0.001 





















0.51 (0.38 – 0.68) 
0.45 (0.33 – 0.62) 






        
Treated 
hypertension 
       
    Yes  266 (7.5) 83 (4.6) 191 (10.5)  0.41 (0.32 – 0.53) <0.001 
    No   292 (6.0) 91 (3.8) 201 (8.1)  0.46 (0.36 – 0.58) <0.001 
Treated 
hyperlipidemia 
       
    Yes  321 (7.1) 106 (4.8) 215 (9.3)  0.48 (0.38 – 0.61) <0.001 
    No   232 (6.1) 67 (3.5) 165 (8.8)  0.39 (0.29 – 0.51) <0.001 
Diabetes        
    Yes  82 (7.9) 30 (5.7) 52 (9.2)  0.52 (0.33 – 0.82) 0.004 
    No   477 (6.5) 144 (3.9) 333 (9.0)  0.42 (0.35 – 0.51) <0.001 
Previous MI        
    Yes  63 (8.3) 22 (6.2) 41 (10.1)  0.57 (0.34 – 0.95) 0.031 
    No   495 (6.5) 151 (3.9) 344 (9.0)  0.42 (0.35 – 0.51) <0.001 
Previous stroke        
    Yes  22 (6.7) 8 (4.9) 14 (8.7)  0.52 (0.22 – 1.24) 0.14 
    No   535 (6.5) 165 (4.1) 370 (9.1)  0.43 (0.36 – 0.52) <0.001 
Previous CABG        
    Yes  40 (10.6) 16 (8.2) 24 (13.2)  0.57 (0.30 – 1.07) 0.08 
     No   520 (6.4) 158 (4.0) 362 (8.9)  0.42 (0.35 – 0.51) <0.001 
Serum creatinine         
     <100 µmol/l  479 (6.6) 150 (4.2) 329 (9.1)  0.44 (0.36 – 0.53) <0.001 
    100 -120 
µmol/l 
 35 (6.0) 11 (3.9) 24 (8.1)  0.47 (0.23 – 0.95) 0.037 
    > 120 µmol/l  14 (5.3) 2 (1.6) 12 (9.1)  0.17 (0.04 – 0.75) 0.020 
No. of diseased 
vessels 
       
    One vessel   294 (5.6) 88 (3.4) 206 (7.8)  0.42 (0.33 – 0.54) <0.001 
    Two vessels           165 (7.2) 46 (3.9) 119 (10.6)  0.36 (0.26 – 0.51) <0.001 
    Three vessels   101 (10.9) 40 (9.0) 61 (12.8)  0.61 (0.41 – 0.90) 0.01 
Abbreviations: BMS, bare-metal stent; DES, drug-eluting stent; HR, hazard ratio; CI, 
confidence interval; MI, myocardial infarction; p, p-value; TLR, target lesion 
revascularization; BMI, body mass index. 
* Number of events (cumulative rate). The cumulative outcome rates (expressed as number (n) 
and percentages (%)) were calculated with the use of Kaplan-Meier the method.  The sum of 
events (n) vary due to missing observations for some variables. 
┼ Hazard ratios and p-values were adjusted for study center in the Cox proportional hazard 
model.   
 
  
Table 3.  Target lesion revascularization in stent- and lesion related variables after 5 years 
in patients with a single lesion treated. 
        
  TLR rates *  DES vs. BMS ┼ 






   
Stent/lesion variables  n (%) n (%) n (%)  HR p 
Total population 
Stent length 
 327 (5.6) 94 (3.3) 233 (7.9)    0.40 (0.31 – 0.50) <0.001 
 <20 mm  176 (5.0) 47 (2.7) 129 (7.1)  0.37 (0.27 – 0.52) <0.001 
 20 – 34 mm  99 (5.8) 28 (3.3) 71 (8.4)  0.39 (0.25 – 0.60) 0.001 
 >34 mm  47(8.4) 16 (5.5) 31 (11.7)  0.43 (0.23 – 0.79) 0.006 
Stent diameter        
 < 3 mm  106 (7.0) 27 (3.6) 79 (10.6)  0.31 (0.20 – 0.47) <0.001 
 3 – 3.9 mm  197 (5.3) 57 (3.1) 140 (7.3)  0.42 (0.31 – 0.57) <0.001 
 >3.9  19 (3.6) 7 (2.5) 12 (4.9)  0.46 (0.18 – 1.16) 0.099 
Delivery pressure        
 <15 bars  51 (6.1) 16 (3.4) 35 (8.7)  0.46 (0.25 – 0.83) 0.01 
 15 -19 bars  94 (5.4) 27 (3.4) 67 (7.2)  0.42 (0.27 – 0.63) <0.001 
 >19 bars  18 (5.7) 6 (3.7) 12(7.7)  0.51 (0.19 – 1.40) 0.19 
Ostial lesion        
 Yes  22 (7.9) 8 (5.6) 14 (10.5)  0.50 (0.21 – 1.22) 0.13 
 No  305 (5.5) 86 (3.1) 219 (7.8)  0.39 (0.30 – 0.50) <0.001 
Visible thrombus        
 Yes   52 (3.8) 16 (2.2) 36 (5.3)  0.44 (0.25 – 0.80) 0.007 
 No   275 (6.2) 78 (3.6) 197 (8.7)  0.39 (0.30 – 0.51) <0.001 
Visible calcification        
 Yes  77 (6.8) 24 (4.2) 53 (9.5)  0.43 (0.26 – 0.69) 0.001 
 No  250 (5.3) 70 (3.2) 180 (7.5)  0.39 (0.29 – 0.51) <0.001 
Bifurcation lesion        
 Yes  46 (7.2) 11 (3.5) 35 (10.7)  0.32 (0.16 – 0.63) 0.001 
 No   281 (5.4) 83 (3.2) 198 (7.6)  0.41 (0.32 – 0.53) <0.001 
Chronic occlusion        
 Yes  18 (11.8) 3 (4.0) 15 (20.5)  0.19 (0.05 – 0.66) 0.009 
 No   309 (5.4) 91 (3.2) 218 (7.6)  0.41 (0.32 – 0.53) <0.001 
Lesion type        
 A  36 (4.6) 4 (1.1) 32 (7.3)  0.15 (0.05 – 0.42) <0.001 
 B1  142 (5.5) 48 (3.7) 94 (7.2)  0.50 (0.36 – 0.71) <0.001 
 B2  67 (5.6) 12 (2.2) 55 (8.8)  0.22 (0.12 – 0.41) <0.001 
 C  82 (6.5) 30 (4.4) 52 (8.9)  0.48 (0.31 – 0.76) 0.002 
Degree of stenosis        
 <81%  116 (5.8) 35 (3.7) 81 (7.8)  0.45 (0.30 – 0.67) <0.001 
 81-94%  100 (6.2) 28 (3.5) 72 (9.1)  0.36 (0.23 – 0.56) <0.001 
 95-100%  111 (4.9) 31 (2.7) 80 (7.1)  0.37 (0.25 – 0.56) <0.001 
TIMI flow ╪        
 0  71 (5.5) 19 (2.9) 52 (8.0)  0.33 (0.19 – 0.55) <0.001 
 1  13 (5.9) 4 (3.7) 9 (8.0)  0.52 (0.16 – 1.70) 0.27 
 2  37 (5.2) 10 (2.8) 27 (7.5)  0.37 (0.18 – 0.77) 0.008 
 3  206 (5.7) 61 (3.4) 145 (7.9)  0.41 (0.31 – 0.56) <0.001 
Use of GPI        
 Yes  60 (4.9) 19 (3.1) 41 (6.6)  0.45 (0.26 – 0.78) 0.004 
 No  267 (5.8) 75 (3.3) 192 (8.3)  0.38 (0.29 – 0.50) <0.001 
Abbreviations: BMS, bare-metal stent; DES, drug-eluting stent; GPI; Glycoprotein IIb/IIIa 
inhibitor.HR, hazard ratio; TIMI, thrombolysis in myocardial infarction; p, p-value; TLR, 
target lesion revascularization.  * Number of events (cumulative rate). The cumulative 
outcome rates (expressed as number (n) and percentages (%)) were calculated with the use 
of Kaplan-Meier the method.   
┼ Hazard ratios and p-values were adjusted for study center in the Cox proportional hazard 
model.  ╪ Preintervention TIMI flow 
 
  
Table 4.  Predictors for target lesion revascularization in patients with one treated lesion in 
native coronary arteries and time-dependent effect of type of stent. 
        
Time invariant 
variables 
 HR  95 % CI  p 
 Age (/5years)  0.89  0.84 – 0.94  <0.001 
 Gender *  0.76  0.59 – 0.97  0.025 
 Two vessels disease ┼  1.39  1.04 – 1.86  0.027 
 Three vessels disease   2.02  1.42 – 2.87  <0.001 
 Visible thrombus in 
the lesion 
 0.59  0.44 – 0.79  <0.001 
 Stent length (/5 mm)  1.11  1.08 – 1.16  <0.001 
 Stent diameter (mm)  0.62  0.49 – 0.79  <0.001 
Covariate with time-
dependent effect 
      
 DES/BMS ╪ 
At 6 months                                                          
At 1 year 
At 2 years 









0.16 – 0.31 
0.29 – 0.50 
0.53 – 1.12 







Abbreviations: CI, confidence interval; HR, hazard ratio; p, p-value 
* Female gender as reference group 
┼ One vessel disease as reference group. 
╪ BMS as reference group 
 
 
